

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州藥業股份有限公司

Guangzhou Pharmaceutical Company Limited

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

CLARIFICATION ANNOUNCEMENT

Guangzhou Pharmaceutical Company Limited (the “Company”) issues this announcement to clarify the matters mentioned below:

1. The Rumors

Recently, Hong Kong Economic Journal, other medias and the internet reported that Mr. Zhu Xinli, chairman of China Huiyuan Juice Group Limited (“Huiyuan Juice”), intended to sell approximate 42% of the equity interest he held in Huiyuan Juice, at approximately RMB2.5 billion (“Relevant Media Reports”) and the potential buyer included the Company.

2. Clarification and Statement

With regard to the Relevant Media Reports on the Company’s intention to acquire the equity interest in Huiyuan Juice, the Company hereby clarifies as follows:

After investigation, the Company verifies that the relevant media reports about the intended acquisition of equity interest in Huiyuan Juice by the Company is untrue. The Company has not been in any negotiation with Huiyuan Juice on the acquisition of the equity interest of Huiyuan Juice.

3. Risk Warning

The Company wishes to inform the investors that the Company’s designated media for publication of its information include Shanghai Securities News, Securities Times, the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>) and the website of The Stock

Exchange of Hong Kong Limited (<http://www.hkex.com.hk>). Investors are advised to take due care to the investment risks.

The Board of
Guangzhou Pharmaceutical Company Limited

Guangzhou, the PRC, 25 March 2013

As at the date of this announcement, the board of the Company comprises Mr. Yang Rongming, Mr. Li Chuyuan, Ms. Cheng Ning and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.